# TrianecT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trianect

- Industry: Medical Devices & Equipment
- Headquarters: Utrecht, Netherlands
- Website: www.trianect.com/
- Total disclosed funding: $1.6M
- Latest round: Seed (Jul 8, 2025)
- Investors on record: 1

## About

Based in the Netherlands, TrianecT BV specializes in innovative stroke diagnosis solutions, enhancing emergency medical services with advanced technology for efficient patient triage and care.TrianecT BV, founded in 2022 and headquartered in Utrecht, Netherlands, focuses on developing solutions for stroke diagnosis. The company raised EUR 1.35 mn in July 2025 from investors CbusineZ and XO Ventures, marking its latest funding round which completed its total fundraising.TrianecT BV specializes in innovative stroke diagnosis solutions, primarily through its flagship product, StrokePointer™. This advanced technology allows for the real-time acquisition and automatic analysis of electrical brain activity (EEG) within the ambulance setting, facilitating the rapid diagnosis of stroke. By enabling emergency medical service (EMS) personnel to triage patients effectively, StrokePointer™ aims to direct patients to the appropriate hospital for timely endovascular treatment, critically reducing the time to care. TrianecT's products are designed for use by EMS providers and healthcare institutions, addressing the urgent need for rapid stroke intervention in various geographical markets, including major urban centers across Europe and North America.TrianecT operates a business model based on direct partnerships with healthcare providers and EMS organizations. Revenue is generated through the sale and potential subscription-based access to their StrokePointer™ technology, which may include ongoing support and updates. The transaction structure typically involves agreements with hospitals and EMS agencies, where they procure the technology for integration into their emergency response protocols. This model ensures that clients remain at the forefront of stroke management innovation while fostering long-term relationships. The pricing details for StrokePointer™ and associated services are determined through negotiated contracts, tailored to the specific needs of each EMS and healthcare partner.In July 2025, TrianecT BV raised EUR 1.35 mn in venture funding to support the commercial development and market launch of a portable stroke detection device for ambulance triage. The company plans to expand its market reach, targeting major urban centers in Europe and North America for this new technology. The funding will enhance their capabilities and facilitate the introduction of this innovative product to improve emergency stroke response.

## Funding rounds

- Seed, Jul 8, 2025, $1.6M — XO Ventures

## Investors

- XO Ventures (https://capitalatlas.ai/funds/xo-ventures) — Seed